Efficacy of folinic acid in preventing oral mucositis in allogeneic hematopoietic stem cell transplant patients receiving MTX as prophylaxis for GVHD

Bone Marrow Transplantation

Volumn 47, Issue 2, 2012, Pages 258-264

  Sugita, J ^a   Matsushita, T ^a   Kashiwazaki, H ^a   Kosugi, M ^a   Takahashi, S ^a   Wakasa, K ^a   Shiratori, S ^a   Ibata, M ^a   Shono, Y ^a   Shigematsu, A ^a   Obara, M ^a   Fujimoto, K ^a   Endo, T ^a   Nishio, M ^a   Kondo, T ^a   Hashino, S ^a   Tanaka, J ^a   Asaka, M ^b   Imamura, M ^a  

^a HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

folinic acid; oral mucositis; SCT

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETOPOSIDE; FOLINIC ACID; METHOTREXATE; MOUTHWASH; TACROLIMUS;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MALE; NEUTROPENIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK REDUCTION; STOMATITIS; WHOLE BODY RADIATION;

EID: 84857034929     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2011.53     Document Type: Article

References (28)

1. Takahashi K, Soga Y, Murayama Y, Udagawa M, Nishimoto H, Sugiura Y et al. Oral mucositis in patients receiving reduced-intensity regimens for allogeneic hematopoietic cell transplantation: comparison with conventional regimen. Support Care Cancer 2010; 18: 115-119.
2. Vokurka S, Steinerova K, Karas M, Koza V. Characteristics and risk factors of oral mucositis after allogeneic stem cell transplantation with FLU/MEL conditioning regimen in context with BU/CY2. Bone Marrow Transplant 2009; 44: 601-605.
3. Langner S, Staber P, Schub N, Gramatzki M, Grothe W, Behre G et al. Palifermin reduces incidence and severity of oral mucositis in allogeneic stem-cell transplant recipients. Bone Marrow Transplant 2008; 42: 275-279.
4. Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert M, Hauer-Jensen M et al. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 2004; 100: 1995-2025. (Pubitemid 38528741)
5. Sonis ST, Oster G, Fuchs H, Bellm L, Bradford WZ, Edelsberg J et al. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol 2001; 19: 2201-2205. (Pubitemid 32372323)
6. Cutler C, Li S, Kim H, Laglenne P, Szeto K, Hoffmeister L et al. Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate-and non-methotrexate-containing graft-versus-host disease prophylaxis regimens. Biol Blood Marrow Transplant 2005; 11: 383-388. (Pubitemid 40542931)
7. Bolwell B, Sobecks R, Pohlman B, Andresen S, Rybicki L, Kuczkowski E et al. A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation. Bone Marrow Transplant 2004; 34: 621-625. (Pubitemid 39341543)
8. Torres A, Martinez F, Gomez P, Herrera C, Rojas R, Gomez-Villagran JL et al. Cyclosporin A versus methotrexate, followed by rescue with folinic acid as prophylaxis of acute graft-versus-host disease after bone marrow transplantation. Blut 1989; 58: 63-68. (Pubitemid 19061008)
9. Nevill TJ, Tirgan MH, Deeg HJ, Klingemann HG, Reece DE, Shepherd JD et al. Influence of post-methotrexate folinic acid rescue on regimen-related toxicity and graft-versus-host disease after allogeneic bone marrow transplantation. Bone Marrow Transplant 1992; 9: 349-354.
10. Russell JA, Woodman RC, Poon MC, Jones AR, Ruether BA. Addition of low-dose folinic acid to a methotrexate/cyclospor-in A regimen for prevention of acute graft-versus-host disease. Bone Marrow Transplant 1994; 14: 397-401. (Pubitemid 24295232)
11. Ruutu T, Niederwieser D, Gratwohl A, Apperley JF. A survey of the prophylaxis and treatment of acute GVHD in Europe: a report of the European Group for Blood and Marrow, Transplantation (EBMT). Chronic Leukaemia Working Party of the EBMT. Bone Marrow Transplant 1997; 19: 759-764. (Pubitemid 27207889)
12. Bhurani D, Schifter M, Kerridge I. Folinic acid administration following MTX as prophylaxis for GVHD in allogeneic HSCT centres in Australia and New Zealand. Bone Marrow Transplant 2008; 42: 547-550.
13. Shigematsu A, Kondo T, Yamamoto S, Sugita J, Onozawa M, Kahata K et al. Excellent outcome of allogeneic hematopoietic stem cell transplantation using a conditioning regimen with medium-dose VP-16, cyclophosphamide and total-body irradiation for adult patients with acute lymphoblastic leukemia. Biol Blood Marrow Transplant 2008; 14: 568-575. (Pubitemid 351494749)
14. Takahata M, Hashino S, Okada K, Onozawa M, Kahata K, Sugita J et al. Reduced intensity conditioning regimen with fludarabine, busulfan, and low-dose TBI (Flu-BU2-TBI): clinical efficacy in high-risk patients. Am J Hematol 2010; 85: 243-248.
15. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825-828.
16. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann stat 1988; 16: 1141-1154.
17. Vokurka S, Bystricka E, Koza V, Scudlova J, Pavlicova V, Valentova D et al. Higher incidence of chemotherapy induced oral mucositis in females: a supplement of multivariate analysis to a randomized multicentre study. Support Care Cancer 2006; 14: 974-976.
18. Vokurka S, Bystricka E, Koza V, Scudlova J, Pavlicova V, Valentova D et al. The comparative effects of povidone-iodine and normal saline mouthwashes on oral mucositis in patients after high-dose chemotherapy and APBSCT-results of a randomized multicentre study. Support Care Cancer 2005; 13: 554-558. (Pubitemid 40933614)
19. Gratwohl A. Folinic acid administration following MTX as prophylaxis for GVHD. Bone Marrow Transplant 2009; 44: 257.
20. Gratwohl AA, Bull MI, Graw RG, Norton L, Knutsen T. Methotrexate and citrovorum factor after histoincompatible allogeneic bone marrow transplants in dogs. Acta Haematol 1978; 60: 233-242. (Pubitemid 8407019)
21. Gratwhol A, Deisseroth A. Suppression of humoral immune response with methotrexate and citroforum factor. In: International Society of Chemotherapy (eds) Current Chemotherapy. American Society for Microbiology: Washington, DC, USA, 1978, pp 1262-1263.
22. Peters C, Minkov M, Gadner H, Klingebiel T, Vossen J, Locatelli F et al. Statement of current majority practices in graft-versus-host disease prophylaxis and treatment in children. Bone Marrow Transplant 2000; 26: 405-411. (Pubitemid 30649556)
23. Gori E, Arpinati M, Bonifazi F, Errico A, Mega A, Alberani F et al. Cryotherapy in the prevention of oral mucositis in patients receiving low-dose methotrexate following myelo-ablative allogeneic stem cell transplantation: a prospective randomized study of the Gruppo Italiano Trapianto di Midollo Osseo nurses group. Bone Marrow Transplant 2007; 39: 347-352. (Pubitemid 46403926)
24. Stark AN, Jackson G, Carey PJ, Arfeen S, Proctor SJ. Severe renal toxicity due to intermediate-dose methotrexate. Cancer Chemother Pharmacol 1989; 24: 243-245. (Pubitemid 19176806)
25. van den Bongard HJ, Matĥt RA, Boogerd W, Schornagel JH, Soesan M, Schellens JH et al. Successful rescue with leucovorin and thymidine in a patient with high-dose methotrexate induced acute renal failure. Cancer Chemother Pharmacol 2001; 47: 537-540. (Pubitemid 32477302)
26. Craig JV, Gibson F, Glenny AM, On behalf of Children's Cancer and Leukaemia Group and Paediatric Oncology Nurses Forum (CCLG-PONF) Mouth Care Group. Audit to monitor the uptake of national mouth care guidelines for children and young people being treated for cancer. Support Care Cancer 2010 (e-pub ahead of print 31 July 2010; doi: 10.1007/s00520-010-0953-3).
27. Hoyt R, Ritchie DS, Wirth A, Szer J, Grigg AP. Etoposide induces more severe mucositis than CY when added to TBI as conditioning in allograft recipients receiving CsA and MTX. Bone Marrow Transplant 2010; 45: 1457-1462.
28. Robien K, Schubert M, Bruemmer B, Lloid M, Potter J, Ulrich C Predictors of oral mucositis in patients receiving hematopoietic cell transplants for chronic myelogenous leukemia. J Clin Oncol 2004; 22: 1268.